Cara Therapeutics

Tvardi to go public via merger with cash-strapped Cara

Pruritus drug developer Cara kicked off the year halving its headcount and has now found a new home via a merger with fibrosis disease-focused Tvardi.

James Waldron Dec 18, 2024 10:37am

Photo of a 100 bill about to be cut with scissors

Itch treater Cara cuts 50% of team to extend runway into 2026

Jan 22, 2024 9:44am

Mirati CMO, COO booted as request to FDA looms—Chutes & Ladders

Nov 5, 2021 9:30am

After securing first FDA nod in 17-year stint, Cara CEO departs

Nov 3, 2021 10:35am

Cara's stock tanks as atopic dermatitis phase 2 misses endpoint

Apr 30, 2021 8:25am

Cara posts positive phase 3 data, eyes 2020 filing for itch drug

Apr 21, 2020 7:00am